WO2006015606A1 - New method for dopamine measurement and diagnoses and following up of psychosis - Google Patents
New method for dopamine measurement and diagnoses and following up of psychosis Download PDFInfo
- Publication number
- WO2006015606A1 WO2006015606A1 PCT/EG2005/000016 EG2005000016W WO2006015606A1 WO 2006015606 A1 WO2006015606 A1 WO 2006015606A1 EG 2005000016 W EG2005000016 W EG 2005000016W WO 2006015606 A1 WO2006015606 A1 WO 2006015606A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dopamine
- urine
- new
- psychosis
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/9413—Dopamine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia
Definitions
- HPLC technique has been applied for determination of dopamine in pharmaceutical products and urine samples at the same time. But HPLC is not an economical method, where it cost lots of money and need a long time since collecting urine of 24 hours till separation of dopamine from this collection. According to Medical view
- Schizophrenia is diagnosed according to some symptoms including hallucination, delusions and behavioral disturbance, and other symptoms which are classified in [DSM-VI, ICD-IO]. There is always some dissimilarity between psychiatrists in looking to the symptom. So, we are in need for a laboratory test helping us in diagnosis. There are no specific symptoms help doctors to detect that Ins patient is going to be relapsed soon. And there was no test that can be used for follow up of persons at high risk of the disease to prevent the disease before it occurs. According to Analytical Chemistry
- a new in this patent Microdetermination of dopamine in urine samples of psychotic patient e.g. schizophrenic patients using spectrophotometric technique.
- This technique is applied for diagnosis, and it help in following up the response of patient to the suggested treatment. It is rapid and economical method and not costing a lot of money.
- This colouring sheet used with urine samples of psychotic patient e.g. schizophrenic patients but not in pharmaceutical products. According to Medical view
- This method helps all doctors especially psychiatrists for early diagnosis and follows up of psychotic patients especially schizophrenic patients.
- Our new methodology can be applied using spectrophotometer or fast analysis by comparing the colouring reaction of urine in a test tube with a standard colouring sheet, which give us an indication of dopamine concentration in the urine.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
This invention relates to a new rapid and economical spectrophotometric method was applied for microdetermination of dopamine in pharmaceutical preparations and in urine samples of psychotic patients e.g. schizophrenic patients. This procedure depends on the formation of coloured complex between dopamine, copper sulfate and 4aminoantipyrine under selected optimum conditions. The proposed procedure can be applied (1) to control the quantity of dopamine in pharmaceutical preparations (2) with psychiatric physician, which allows them to (a) detection the psychosis early which help in treatment and prevention of the disease e.g. screen study (b) diagnose of the disease (c) follow up the schizophrenic patients, (d) to control the dose of treatment and (f) prevention of relapse in patients on anti-psychotic drugs or with history of the disease.
Description
New method for dopamine measurement and diagnoses and following up of psychosis
Technical Field:
1- New analytical method applied in microdeteπnination of dopamine in urine samples and in pharmaceutical preparations using spectrophotometer.
2- New method for diagnose, follow up, prevention and relapse prevention of psychosis e.g. schizophrenia.
Background Art
According to Analytical Chemistry
Many spectrophotometric procedures have been applied for quantitative determination of dopamine in pharmaceutical products, but not in urine due to a lot of interference. HPLC technique has been applied for determination of dopamine in pharmaceutical products and urine samples at the same time. But HPLC is not an economical method, where it cost lots of money and need a long time since collecting urine of 24 hours till separation of dopamine from this collection. According to Medical view
Schizophrenia is diagnosed according to some symptoms including hallucination, delusions and behavioral disturbance, and other symptoms which are classified in [DSM-VI, ICD-IO]. There is always some dissimilarity between psychiatrists in looking to the symptom. So, we are in need for a laboratory test helping us in diagnosis. There are no specific symptoms help doctors to detect that Ins patient is going to be relapsed soon. And there was no test that can be used for follow up of persons at high risk of the disease to prevent the disease before it occurs. According to Analytical Chemistry
- Spectrophotometric determination of dopamine could not been applied in urine samples due to a lot of interfering reactions. - HPLC technique is not economical method, where it cost a lot of money and need a long time since collecting urine of 24 hours till separation and analysis of dopamine from this collection.
According to Medical view
Overlapping in symptoms leads to dissimilarities between doctors in diagnosing the disease. Also in the past, early detection of relapse before occurring is not that easy. When the disease occur and starting
medication, we need 6-8 weeks to detect patient's response to the drug and waiting another 6-8 weeks to detect patient's response to a new drug if the first was not suitable.
Disclosure of Invention:
According to Analytical Chemistry
A new in this patent: Microdetermination of dopamine in urine samples of psychotic patient e.g. schizophrenic patients using spectrophotometric technique. This technique is applied for diagnosis, and it help in following up the response of patient to the suggested treatment. It is rapid and economical method and not costing a lot of money. In this technique we can also compare the net result of urine analysis with a standard colouring strips, without needing spectrophotometric apparatus, to detect that if the amount of dopamine in normal range or more then normal range required. This colouring sheet used with urine samples of psychotic patient e.g. schizophrenic patients but not in pharmaceutical products. According to Medical view
Ability to diagnose psychosis e.g. schizophrenia using laboratory test. Early diagnose of psychosis by routine examination of urine as in diabetic patients, which can be used in (military service, before employ, before driving license, at school, before college acceptance, ) .
Distinguish between dementia and psychosis.
Distinguish between delirious and psychosis. hi deaf mute with psychotic symptoms where communication with doctor is not that easy
Follow up of patient's response after two weeks from medication by using our new test.
Reducing the number of relapses which cause deterioration in psychotic mental functions.
- Prevention of the disease in high risk persons by regular follow up using our new test (spectrophotometricaly or standard colouring strips).
Best mode for carrying out the invention:
- Our new spectrophotometric method depends on the reaction of dopamine concentration with copper sulfate and 4-aminoantipyrine under selected optimum conditions (pH, time, temperature, wavelength and ratio of reagents). In addition to that we make a modification to simplify the method by preparing standard colouring strip which can be used as indicator of dopamine concentration in urine.
Industrial Applicability:
- Our new methodology depends on using easy, simple and economic equipment (spectrophotometer or standard colouring strip test) which can be applied in all laboratories unites especially in psychiatric hospitals, out patients' climes and privet clinics or screening.
This method helps all doctors especially psychiatrists for early diagnosis and follows up of psychotic patients especially schizophrenic patients. Our new methodology can be applied using spectrophotometer or fast analysis by comparing the colouring reaction of urine in a test tube with a standard colouring sheet, which give us an indication of dopamine concentration in the urine.
- Microdetermination of dopamine concentration can be applied quantitatively in pharmaceutical products using our new procedure in all pharmaceutical companies.
Claims
Claims
- Our new spectropliotometric method is a quantitative procedure, which can be applied in microdetermination of dopamine concentration in pharmaceutical products that contain dopamine and in the urine of psychotic patients e.g. schizophrenics. It depends on the reaction of dopamine with copper sulfate and 4- aminoantipyrine under optimum conditions (pH, temperature, time, wavelength and ratio of reagents). This procedure is modified and simplified by comparing the colour of test with a standard colouring strip to detect quantitatively the concentration of dopamine in urine.
- According to claim (1) the collection of one urine sample from the person.
- According to claim (2) the detection of dopamine is carrying out using spectrophotometer or standard colouring strip.
- According to claim (3) the dopamine react woth copper solfat for aminoantipyrine under optimum condition (pH, temperature, time, wavelength and ratio of reagents)
- The quantative detection of dopamine in pharmaceutical products do not need any separation before analyses.
- Diagnose, follow up and relapse prevention of psychotic patients e.g. schizophrenia using our new spectrophotometric method .
- Using our new method and its modifacation (standard colouring strip test) as a routine analysis in all laboratories for early detection of psychosis in high risk persons , in screening or survey study, or for persons not known to be of high risk.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002581262A CA2581262A1 (en) | 2004-08-08 | 2005-05-22 | New method for dopamine measurement and diagnoses and following up of psychosis |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EG2004080337 | 2004-08-08 | ||
| EG2004080337 | 2004-08-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2006015606A1 true WO2006015606A1 (en) | 2006-02-16 |
Family
ID=35839152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EG2005/000016 Ceased WO2006015606A1 (en) | 2004-08-08 | 2005-05-22 | New method for dopamine measurement and diagnoses and following up of psychosis |
Country Status (2)
| Country | Link |
|---|---|
| CA (1) | CA2581262A1 (en) |
| WO (1) | WO2006015606A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015063563A1 (en) * | 2013-10-30 | 2015-05-07 | Dh Technologies Development Pte. Ltd. | Mass spectrometric identification and/or quantitation of catecholamines using aminopyrazoles |
| CN108693126A (en) * | 2017-04-05 | 2018-10-23 | 中国科学院大连化学物理研究所 | A kind of rapid detection method of carbamate chemicals for agriculture |
-
2005
- 2005-05-22 WO PCT/EG2005/000016 patent/WO2006015606A1/en not_active Ceased
- 2005-05-22 CA CA002581262A patent/CA2581262A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| MOHAMED G.G. ET AL: "IR, UV-Vis, magnetic and thermal characterization of chelates of some catecholamines and 4-aminoantipyrine with Fe(III) and Cu(II)", SPECTROCHIM ACTA A MOL BIOMOL SPECTROSC., vol. 60, no. 8-9, 2004, pages 1775 - 1781 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015063563A1 (en) * | 2013-10-30 | 2015-05-07 | Dh Technologies Development Pte. Ltd. | Mass spectrometric identification and/or quantitation of catecholamines using aminopyrazoles |
| US9964552B2 (en) | 2013-10-30 | 2018-05-08 | Dh Technologies Development Pte. Ltd. | Mass spectrometric identification and/or quantitation of catecholamines using aminopyrazoles |
| CN108693126A (en) * | 2017-04-05 | 2018-10-23 | 中国科学院大连化学物理研究所 | A kind of rapid detection method of carbamate chemicals for agriculture |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2581262A1 (en) | 2006-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3022560B1 (en) | Blood-based screen for detecting neurological diseases in primary care settings | |
| Tsai et al. | Comparison and interpretation of urinalysis performed by a nephrologist versus a hospital-based clinical laboratory | |
| Attema-de Jonge et al. | Performance of three point-of-care urinalysis test devices for drugs of abuse and therapeutic drugs applied in the emergency department | |
| Racine et al. | The personalized Alzheimer's disease cortical thickness index predicts likely pathology and clinical progression in mild cognitive impairment | |
| Lutz et al. | A genetics-based biomarker risk algorithm for predicting risk of Alzheimer's disease | |
| Stoven et al. | Analysis of biopsies from duodenal bulbs of all endoscopy patients increases detection of abnormalities but has a minimal effect on diagnosis of celiac disease | |
| Zhang et al. | A strategy for the development of biomarker tests for PTSD | |
| US20140018299A1 (en) | Method and device to detect, monitor and promote neural regeneration and improvement of cognitive function in a subject suffering from neural injury | |
| US20220214365A1 (en) | Methods of Detecting Anti-folic acid Antibodies and Uses Thereof | |
| EP3139922B1 (en) | Methods of diagnosing and treating tuberculosis | |
| Appel-Cresswell et al. | PSEN1 p. Met233Val in a complex neurodegenerative movement and neuropsychiatric disorder | |
| WO2006015606A1 (en) | New method for dopamine measurement and diagnoses and following up of psychosis | |
| US20120077278A1 (en) | Methods and kits for detecting, diagnosing and monitoring diseases | |
| CN101010589A (en) | Biomarkers of alzheimer's disease | |
| Hu et al. | Application of cerebrospinal fluid free light chain in diagnosis of primary central nervous system lymphoma and monitoring of associated chemotherapy efficacy | |
| Mutapi | Improving diagnosis of urogenital schistosome infection | |
| Vermeersch et al. | Use of interval-specific likelihood ratios improves clinical interpretation of serum FLC results for the diagnosis of malignant plasma cell disorders | |
| WO2018210395A1 (en) | Lateral flow chromatographic assay for tuberculosis (tb) | |
| Phelan et al. | An analysis of relative costs and potential benefits of different policies for antenatal screening for beta thalassaemia trait and variant haemoglobins. | |
| Linder et al. | Detection of cocaine metabolite in serum and urine: frequency and correlation with medical diagnosis | |
| US20110269246A1 (en) | Measuring levels of frataxin | |
| Luzzi | Point of care devices for drugs of abuse testing: limitations and pitfalls | |
| Lea | Multiplex planar microarrays for disease prognosis, diagnosis and theranosis | |
| Selvamani et al. | Diagnostic test evaluation: Design, measures, and classic examples | |
| Hussein et al. | Emerging Biomarkers for Diagnosing Autoimmune Diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2581262 Country of ref document: CA |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |